GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » Revenue per Share

Medlab Clinical (Medlab Clinical) Revenue per Share : $0.10 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical Revenue per Share?

Medlab Clinical's revenue per share for the six months ended in Dec. 2023 was $0.01. Medlab Clinical's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.10.

Warning Sign:

Medlab Clinical Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Medlab Clinical was -76.30% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -40.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Medlab Clinical's Revenue per Share or its related term are showing as below:

MDBBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.9   Med: -11.6   Max: 179.9
Current: -40.9

During the past 8 years, Medlab Clinical's highest 3-Year average Revenue Per Share Growth Rate was 179.90% per year. The lowest was -40.90% per year. And the median was -11.60% per year.

MDBBF's 3-Year Revenue Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.5 vs MDBBF: -40.90

Medlab Clinical Revenue per Share Historical Data

The historical data trend for Medlab Clinical's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Revenue per Share Chart

Medlab Clinical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Revenue per Share
Get a 7-Day Free Trial 2.71 1.31 1.71 60.07 0.26

Medlab Clinical Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.26 0.18 0.09 0.01

Competitive Comparison of Medlab Clinical's Revenue per Share

For the Biotechnology subindustry, Medlab Clinical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's PS Ratio distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's PS Ratio falls into.



Medlab Clinical Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Medlab Clinical's Revenue Per Share for the fiscal year that ended in Jun. 2023 is calculated as

Revenue Per Share (A: Jun. 2023 )=Revenue (A: Jun. 2023 )/Shares Outstanding (Diluted Average) (A: Jun. 2023 )
=0.599/2.284
=0.26

Medlab Clinical's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=0.032/2.284
=0.01

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlab Clinical  (OTCPK:MDBBF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Medlab Clinical Revenue per Share Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical (Medlab Clinical) Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

Medlab Clinical (Medlab Clinical) Headlines